[Russian recombinant vaccine against hepatitis B (results of controlled trials)].
Two yeast recombinant vaccines were compared: the Russian hepatitis B Combiotech vaccine in a dose of 20 mg and the Recombivax-HB vaccine in a dose of 10 mg manufactured in the USA (Merk, Sharp and Dohme Ltd.). Both agents were found safe and low reactogenic. After a course of 3 vaccinations with the Russian vaccine 92.5 to 97.5% subjects vaccinated after the 0-1-2 months and 0-1-6 months protocols had high levels of specific antibodies. In the group vaccinated with the American vaccine, antibodies to HBsAg were found in the sera of 95 to 100% subjects. These results demonstrate high immunological activity of both Russian and American vaccines.
Pavlova
L I
LI
Gorbunov
M A
MA
Borisova
V N
VN
Krasil'nikov
I V
IV
Noskova
A V
AV
Lytsar'
B N
BN
Skvortsov
S V
SV
Beliakova
E A
EA
Iakovleva
I M
IM
Korovin
Iu P
IuP
Bel'chenko
A V
AV
Titov
I A
IA
Budanov
M V
MV
D000328:Adult; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D017325:Hepatitis B Vaccines / Q000627:therapeutic use*; D006801:Humans; D014614:Vaccines, Synthetic / Q000627:therapeutic use*
D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic